Conflicting Post-Bilski Cases: Classen And CyberSource
What methods cannot be patented, even if they are novel and useful? A deeply divided Federal Circuit panel struggled with that question in Classen Immunotherapies Inc. v. Biogen Idec, No. 2006-1634...To view the full article, register now.
Already a subscriber? Click here to view full article